{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:21:24Z","timestamp":1790097684758,"version":"4.0.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T00:00:00Z","timestamp":1295913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1038\/nrrheum.2010.214","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T11:51:30Z","timestamp":1295956290000},"page":"139-150","source":"Crossref","is-referenced-by-count":142,"title":["Hepatotoxicity related to antirheumatic drugs"],"prefix":"10.1038","volume":"7","author":[{"given":"Guruprasad P.","family":"Aithal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"key":"BFnrrheum2010214_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson, H.  et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56\u201367 (2000).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"BFnrrheum2010214_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ajg.2008.149","volume":"104","author":"L Laine","year":"2009","unstructured":"Laine, L.  et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am. J. Gastroenterol. 104, 356\u2013362 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrrheum2010214_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/bmj.327.7405.18","volume":"327","author":"G Traversa","year":"2003","unstructured":"Traversa, G.  et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 327, 18\u201322 (2003).","journal-title":"BMJ"},{"key":"BFnrrheum2010214_CR4","unstructured":"Scottish Government Health Directorates. Lumiracoxib: suspension of UK licences with immediate effect (non urgent) cascade within 48 hours. SGHD on SHOW \n                    [online]\n                    \n                  , (2007)."},{"key":"BFnrrheum2010214_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","volume":"58","author":"FJ de Abajo","year":"2004","unstructured":"de Abajo, F. J., Montero, D., Madurga, M. & Garc\u00eda Rodr\u00edguez, L. A. Acute and clinically relevant drug-induced liver injury: a population based case\u2013control study. Br. J. Clin. Pharmacol. 58, 71\u201380 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrrheum2010214_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/pds.755","volume":"12","author":"R Paulose-Ram","year":"2003","unstructured":"Paulose-Ram, R.  et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol. Drug Saf. 12, 315\u2013326 (2003).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"BFnrrheum2010214_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cld.2007.06.004","volume":"11","author":"GP Aithal","year":"2007","unstructured":"Aithal, G. P. & Day, C. P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin. Liver Dis. 11, 563\u2013575 (2007).","journal-title":"Clin. Liver Dis."},{"key":"BFnrrheum2010214_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2036.2004.02092.x","volume":"20","author":"JH Rubenstein","year":"2004","unstructured":"Rubenstein, J. H. & Laine, L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 20, 373\u2013380 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrrheum2010214_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00001648-199311000-00004","volume":"4","author":"S Perez Gutthann","year":"1993","unstructured":"Perez Gutthann, S. & Garc\u00eda Rodr\u00edguez, L. A. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 4, 496\u2013501 (1993).","journal-title":"Epidemiology"},{"key":"BFnrrheum2010214_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/archinte.154.3.311","volume":"154","author":"LA Garc\u00eda Rodr\u00edguez","year":"1994","unstructured":"Garc\u00eda Rodr\u00edguez, L. A., Williams, R., Derby, L. E., Dean, A. D. & Jick, H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch. Intern. Med. 154, 311\u2013316 (1994).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum2010214_CR11","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/hep.1840220320","volume":"22","author":"AT Banks","year":"1995","unstructured":"Banks, A. T., Zimmerman, H. J., Ishak, K. G. & Harter, J. G. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22, 820\u2013827 (1995).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/s-2002-30102","volume":"22","author":"S Chitturi","year":"2002","unstructured":"Chitturi, S. & George, J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 22, 169\u2013183 (2002).","journal-title":"Semin. Liver Dis."},{"key":"BFnrrheum2010214_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1517\/14740338.3.6.519","volume":"3","author":"GP Aithal","year":"2004","unstructured":"Aithal, G. P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin. Drug Saf. 3, 519\u2013523 (2004).","journal-title":"Expert Opin. Drug Saf."},{"key":"BFnrrheum2010214_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/00008571-200008000-00004","volume":"10","author":"GP Aithal","year":"2000","unstructured":"Aithal, G. P., Day, C. P., Leathart, J. B. & Daly, A. K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10, 511\u2013518 (2000).","journal-title":"Pharmacogenetics"},{"key":"BFnrrheum2010214_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/0008-5472.CAN-05-2857","volume":"66","author":"J Thibaudeau","year":"2006","unstructured":"Thibaudeau, J.  et al. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66, 125\u2013133 (2006).","journal-title":"Cancer Res."},{"key":"BFnrrheum2010214_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clpt.2003.10.006","volume":"75","author":"Y Duguay","year":"2004","unstructured":"Duguay, Y., B\u00e1\u00e1r, C., Skorpen, F. & Guillemette, C. A novel functional polymorphism in the uridine diphosphate\u2013glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 75, 223\u2013233 (2004).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrrheum2010214_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","volume":"132","author":"AK Daly","year":"2007","unstructured":"Daly, A. K.  et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272\u2013281 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrrheum2010214_CR18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/bdra.20023","volume":"70","author":"LE Jensen","year":"2004","unstructured":"Jensen, L. E.  et al. A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifida. Birth Defects Res. A Clin. Mol. Teratol. 70, 396\u2013399 (2004).","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"BFnrrheum2010214_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/sj.tpj.6500403","volume":"7","author":"S Haenisch","year":"2007","unstructured":"Haenisch, S.  et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 7, 56\u201365 (2007).","journal-title":"Pharmacogenomics J."},{"key":"BFnrrheum2010214_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai, D.  et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597\u2013607 (2001).","journal-title":"Pharmacogenetics"},{"key":"BFnrrheum2010214_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"N Bahadur","year":"2002","unstructured":"Bahadur, N.  et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6a-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64, 1579\u20131589 (2002).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrrheum2010214_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0009-9236(03)00228-5","volume":"74","author":"M Niemi","year":"2003","unstructured":"Niemi, M.  et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74, 380\u2013387 (2003).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrrheum2010214_CR23","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.20205","volume":"39","author":"GP Aithal","year":"2004","unstructured":"Aithal, G. P.  et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39, 1430\u20131440 (2004).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0300-483X(02)00255-X","volume":"181","author":"M Pirmohamed","year":"2002","unstructured":"Pirmohamed, M., Naisbitt, D. J., Gordon, F. & Park, B. K. The danger hypothesis\u2014potential role in idiosyncratic drug reactions. Toxicology 181\u2013182, 55\u201363 (2002).","journal-title":"Toxicology"},{"key":"BFnrrheum2010214_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd1750","volume":"4","author":"N Kaplowitz","year":"2005","unstructured":"Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489\u2013499 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrrheum2010214_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/0016-5085(93)90428-F","volume":"104","author":"EM Tarazi","year":"1993","unstructured":"Tarazi, E. M., Harter, J. G., Zimmerman, H. J., Ishak, K. G. & Eaton, R. A. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 104, 569\u2013574 (1993).","journal-title":"Gastroenterology"},{"key":"BFnrrheum2010214_CR27","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0016-5085(99)70356-2","volume":"117","author":"U Bolder","year":"1999","unstructured":"Bolder, U.  et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 117, 962\u2013971 (1999).","journal-title":"Gastroenterology"},{"key":"BFnrrheum2010214_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2474-9-48","volume":"9","author":"P Jobanputra","year":"2008","unstructured":"Jobanputra, P.  et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet. Disord. 9, 48 (2008).","journal-title":"BMC Musculoskelet. Disord."},{"key":"BFnrrheum2010214_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","volume":"15","author":"H Bocquet","year":"1996","unstructured":"Bocquet, H., Bagot, M. & Roujeau, J. C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin. Cutan. Med. Surg. 15, 250\u2013257 (1996).","journal-title":"Semin. Cutan. Med. Surg."},{"key":"BFnrrheum2010214_CR30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1365-2133.2003.05321.x","volume":"148","author":"T Ohtani","year":"2003","unstructured":"Ohtani, T., Hiroi, A., Sakurane, M. & Furukawa, F. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. Br. J. Dermatol. 148, 1035\u20131039 (2003).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2010214_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3109\/03009749209099228","volume":"21","author":"GD Kitas","year":"1992","unstructured":"Kitas, G. D., Farr, M., Waterhouse, L. & Bacon, P. A. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand. J. Rheumatol. 21, 220\u2013225 (1992).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum2010214_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","volume":"39","author":"P Emery","year":"2000","unstructured":"Emery, P.  et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39, 655\u2013665 (2000).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2010214_CR33","unstructured":"US Food and Drug Administration. Arthritis Advisory Committee slides March 5, 2003: Arava\u00ae(leflunomide). CDER 2003 meeting documents \n                    [online]\n                    \n                  , (2003)."},{"key":"BFnrrheum2010214_CR34","volume-title":"ACR Hotline","author":"E Matteson","year":"2001","unstructured":"Matteson, E. & Cush, J. J. Reports of leflunomide hepatotoxicity in patients with rheumatoid arthritis. August 2001. ACR Hotline \n                    [online]\n                    \n                  , (2001)."},{"key":"BFnrrheum2010214_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","volume":"32","author":"N Alcorn","year":"2009","unstructured":"Alcorn, N. Saunders, S. & Madhok, R. Benefit\u2013risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 32, 1123\u20131134 (2009).","journal-title":"Drug Saf."},{"key":"BFnrrheum2010214_CR36","first-page":"472","volume":"35","author":"PS Helliwell","year":"2008","unstructured":"Helliwell, P. S. & Taylor, W. J. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs\u2014comparison of drugs and adverse reactions. J. Rheumatol. 35, 472\u2013476 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2010214_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1034\/j.1600-0676.2003.00806.x","volume":"23","author":"C Basset","year":"2003","unstructured":"Basset, C., Vadrot, J., Denis, J., Poupon, J. & Zafrani, E. S. Prolonged cholestasis and ductopenia following gold salt therapy. Liver Int. 23, 89\u201393 (2003).","journal-title":"Liver Int."},{"key":"BFnrrheum2010214_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.1840140304","volume":"14","author":"GM Fleischner","year":"1991","unstructured":"Fleischner, G. M.  et al. Light- and electron-microscopical study of a case of gold salt-induced hepatotoxicity. Hepatology 14, 422\u2013425 (1991).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/BF01536001","volume":"33","author":"PB Watkins","year":"1988","unstructured":"Watkins, P. B., Schade, R., Mills, A. S., Carithers, R. L. Jr & van Thiel, D. H. Fatal hepatic necrosis associated with parenteral gold therapy. Dig. Dis. Sci. 33, 1025\u20131029 (1988).","journal-title":"Dig. Dis. Sci."},{"key":"BFnrrheum2010214_CR40","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ibd.20160","volume":"13","author":"JP Gisbert","year":"2007","unstructured":"Gisbert, J. P.  et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13, 1106\u20131114 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrrheum2010214_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.49.1.25","volume":"49","author":"ME Jeurissen","year":"1990","unstructured":"Jeurissen, M. E. Boerbooms, A. M., van de Putte, L. B. & Kruijsen, M. W. Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann. Rheum. Dis. 49, 25\u201327 (1990).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 1","key":"BFnrrheum2010214_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0168-8278(97)82330-6","volume":"26","author":"VJ Desmet","year":"1997","unstructured":"Desmet, V. J. Vanishing bile duct syndrome in drug-induced liver disease. J. Hepatol. 26 (Suppl. 1), 31\u201335 (1997).","journal-title":"J. Hepatol."},{"key":"BFnrrheum2010214_CR43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/gast.2002.32420","volume":"122","author":"MC Dubinsky","year":"2002","unstructured":"Dubinsky, M. C.  et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122, 904\u2013915 (2002).","journal-title":"Gastroenterology"},{"key":"BFnrrheum2010214_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","volume":"5","author":"MP Sparrow","year":"2007","unstructured":"Sparrow, M. P., Hande, S. A., Friedman, S., Cao, D. & Hanauer, S. B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5, 209\u2013214 (2007).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrrheum2010214_CR45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2036.2008.03782.x","volume":"28","author":"A Ansari","year":"2008","unstructured":"Ansari, A.  et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28, 734\u2013741 (2008).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrrheum2010214_CR46","first-page":"469","volume":"35","author":"V Chandran","year":"2008","unstructured":"Chandran, V., Schentag, C. T. & Gladman, D. D. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J. Rheumatol. 35, 469\u2013471 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2010214_CR47","first-page":"1454","volume":"35","author":"WJ Taylor","year":"2008","unstructured":"Taylor, W. J.  et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J. Rheumatol. 35, 1454\u20131457 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2010214_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/ard.55.5.273","volume":"55","author":"W Hassan","year":"1996","unstructured":"Hassan, W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann. Rheum. Dis. 55, 273\u2013275 (1996).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2010214_CR49","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3899\/jrheum.090482","volume":"36","author":"L Kocharla","year":"2009","unstructured":"Kocharla, L.  et al. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J. Rheumatol. 36, 2813\u20132818 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2010214_CR50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot, C. & van der Heijde, D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann. Rheum. Dis. 68, 1100\u20131104 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2010214_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2007.03.017","volume":"46","author":"GP Aithal","year":"2007","unstructured":"Aithal, G. P. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46, 995\u2013998 (2007).","journal-title":"J. Hepatol."},{"key":"BFnrrheum2010214_CR52","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.20278","volume":"50","author":"JM Kremer","year":"2004","unstructured":"Kremer, J. M. Toward a better understanding of methotrexate. Arthritis Rheum. 50, 1370\u20131382 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2010214_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2165\/00003495-200262040-00005","volume":"62","author":"C Desouza","year":"2002","unstructured":"Desouza, C., Keebler, M., McNamara, D. B. & Fonseca, V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 62, 605\u2013616 (2002).","journal-title":"Drugs"},{"key":"BFnrrheum2010214_CR54","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/hep.20708","volume":"41","author":"JM Mato","year":"2005","unstructured":"Mato, J. M. & Lu, S. C. Homocysteine, the bad thiol. Hepatology 41, 976\u2013979 (2005).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR55","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.devcel.2008.11.013","volume":"15","author":"S Basseri","year":"2008","unstructured":"Basseri, S. & Austin, R. C. ER stress and lipogenesis: a slippery slope toward hepatic steatosis. Dev. Cell 15, 795\u2013796 (2008).","journal-title":"Dev. Cell"},{"key":"BFnrrheum2010214_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","volume":"69","author":"JR Curtis","year":"2010","unstructured":"Curtis, J. R.  et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann. Rheum. Dis. 69, 43\u201347 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2010214_CR57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","volume":"19","author":"GP Aithal","year":"2004","unstructured":"Aithal, G. P.  et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment. Pharmacol. Ther. 19, 391\u2013399 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrrheum2010214_CR58","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.080576","volume":"36","author":"MC Fisher","year":"2009","unstructured":"Fisher, M. C. & Cronstein, B. N. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 36, 539\u2013545 (2009).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2010214_CR59","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00228-008-0521-7","volume":"64","author":"P Bohanec Grabar","year":"2008","unstructured":"Bohanec Grabar, P., Logar, D., Lestan, B. & Dolzan, V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol. 64, 1057\u20131068 (2008).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BFnrrheum2010214_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2217\/pgs.09.139","volume":"11","author":"WM Kooloos","year":"2010","unstructured":"Kooloos, W. M.  et al. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11, 163\u2013175 (2010).","journal-title":"Pharmacogenomics"},{"key":"BFnrrheum2010214_CR61","first-page":"572","volume":"35","author":"P Ranganathan","year":"2008","unstructured":"Ranganathan, P.  et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35, 572\u2013579 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2010214_CR62","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","volume":"51","author":"L Miele","year":"2009","unstructured":"Miele, L.  et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 51, 778\u2013786 (2009).","journal-title":"J. Hepatol."},{"key":"BFnrrheum2010214_CR63","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","volume":"90","author":"QE Whiting-O'Keefe","year":"1991","unstructured":"Whiting-O'Keefe, Q. E., Fye, K. H. & Sack, K. D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med. 90, 711\u2013716 (1991).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2010214_CR64","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","volume":"46","author":"P Rosenberg","year":"2007","unstructured":"Rosenberg, P.  et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol. 46, 1111\u20131118 (2007).","journal-title":"J. Hepatol."},{"key":"BFnrrheum2010214_CR65","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1126\/science.1128294","volume":"313","author":"U Ozcan","year":"2006","unstructured":"Ozcan, U.  et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137\u20131140 (2006).","journal-title":"Science"},{"key":"BFnrrheum2010214_CR66","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhep.2006.06.004","volume":"45","author":"C Ji","year":"2006","unstructured":"Ji, C. & Kaplowitz, N. ER stress: can the liver cope? J. Hepatol. 45, 321\u2013333 (2006).","journal-title":"J. Hepatol."},{"key":"BFnrrheum2010214_CR67","doi-asserted-by":"crossref","unstructured":"Katchamart, W., Trudeau, J., Phumethum, V. & Bombardier, C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD008495. doi:10.1002\/14651858.CD008495 (2010).","DOI":"10.1002\/14651858.CD008495"},{"key":"BFnrrheum2010214_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.21258","volume":"44","author":"PA Reshamwala","year":"2006","unstructured":"Reshamwala, P. A., Kleiner, D. E. & Heller, T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 44, 7\u201314 (2006).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR69","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/ard.2002.001826","volume":"63","author":"S Abraham","year":"2004","unstructured":"Abraham, S., Begum, S. & Isenberg, D. Hepatic manifestations of autoimmune rheumatic diseases. Ann. Rheum. Dis. 63, 123\u2013129 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2010214_CR70","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/lt.20377","volume":"11","author":"DP Breen","year":"2005","unstructured":"Breen, D. P., Marinaki, A. M., Arenas, M. & Hayes, P. C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 11, 826\u2013833 (2005).","journal-title":"Liver Transpl."},{"key":"BFnrrheum2010214_CR71","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/00042737-200605000-00018","volume":"18","author":"J Seiderer","year":"2006","unstructured":"Seiderer, J.  et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol. 18, 553\u2013555 (2006).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFnrrheum2010214_CR72","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove, J.  et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann. Rheum. Dis. 69, 1612\u20131617 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2010214_CR73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrd2196","volume":"6","author":"V Strand","year":"2007","unstructured":"Strand, V., Kimberly, R. & Isaacs, J. D. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6, 75\u201392 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrrheum2010214_CR74","unstructured":"US Food and Drug Administration. Important drug warning. FDA MedWatch \n                    [online]\n                    \n                  , (2004)."},{"key":"BFnrrheum2010214_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.amjmed.2004.02.032","volume":"117","author":"S Suissa","year":"2004","unstructured":"Suissa, S., Ernst, P., Hudson, M., Bitton, A. & Kezouh, A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am. J. Med. 117, 87\u201392 (2004).","journal-title":"Am. J. Med."},{"key":"BFnrrheum2010214_CR76","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon, G. J. Ca\u00f1as, C., Jaller, J. J., Restrepo, J. C. & Anaya, J. M. Serious liver disease induced by infliximab. Clin. Rheumatol. 26, 578\u2013581 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum2010214_CR77","doi-asserted-by":"crossref","unstructured":"Mancini, S., Amorotti, E., Vecchio, S., Ponz de Leon, M. & Roncucci, L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern. Emerg. Med. 193\u2013200 (2010).","DOI":"10.1007\/s11739-009-0342-4"},{"key":"BFnrrheum2010214_CR78","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1749-6632.2009.05138.x","volume":"1183","author":"YC Kong","year":"2010","unstructured":"Kong, Y. C., Wei, W. Z. & Tomer, Y. Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. Ann. NY Acad. Sci. 1183, 222\u2013236 (2010).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrrheum2010214_CR79","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan, G. & Benichou, C. Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46, 1323\u20131330 (1993).","journal-title":"J. Clin. Epidemiol."},{"key":"BFnrrheum2010214_CR80","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/pds.1207","volume":"15","author":"L Goldkind","year":"2006","unstructured":"Goldkind, L. & Laine, L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol. Drug Saf. 15, 213\u2013220 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"BFnrrheum2010214_CR81","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E Bj\u00f6rnsson","year":"2005","unstructured":"Bj\u00f6rnsson, E. & Olsson, R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42, 481\u2013489 (2005).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR82","unstructured":"British Society for Rheumatology. National guidelines for the monitoring of second line drugs. Produced by the British Society for Rheumatology July 2000. Guidelines archive \n                    [online]\n                    \n                  , (2000)."},{"key":"BFnrrheum2010214_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/clpt.2008.262","volume":"85","author":"JR Senior","year":"2009","unstructured":"Senior, J. R. Monitoring for hepatotoxicity: what is the predictive value of liver \u201cfunction\u201d tests? Clin. Pharmacol. Ther. 85, 331\u2013334 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrrheum2010214_CR84","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2165\/00128071-200506060-00003","volume":"6","author":"JA Thomas","year":"2005","unstructured":"Thomas, J. A. & Aithal, G. P. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am. J. Clin. Dermatol. 6, 357\u2013363 (2005).","journal-title":"Am. J. Clin. Dermatol."},{"key":"BFnrrheum2010214_CR85","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/bmj.333.7564.380","volume":"333","author":"CH Smith","year":"2006","unstructured":"Smith, C. H. & Barker, J. N. Psoriasis and its management. BMJ 333, 380\u2013384 (2006).","journal-title":"BMJ"},{"key":"BFnrrheum2010214_CR86","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1365-2133.2005.06422.x","volume":"152","author":"RJ Chalmers","year":"2005","unstructured":"Chalmers, R. J.  et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br. J. Dermatol. 152, 444\u2013450 (2005).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2010214_CR87","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2005.06605.x","volume":"152","author":"A MacDonald","year":"2005","unstructured":"MacDonald, A. & Burden, A. D. Noninvasive monitoring for methotrexate hepatotoxicity. Br. J. Dermatol. 152, 405\u2013408 (2005).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2010214_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1373\/49.1.1","volume":"49","author":"PM Bossuyt","year":"2003","unstructured":"Bossuyt, P. M.  et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin. Chem. 49, 1\u20136 (2003).","journal-title":"Clin. Chem."},{"key":"BFnrrheum2010214_CR89","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","volume":"47","author":"IN Guha","year":"2008","unstructured":"Guha, I. N.  et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47, 455\u2013460 (2008).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR90","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jhep.2010.04.043","volume":"53","author":"D Laharie","year":"2010","unstructured":"Laharie, D.  et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case\u2013control study. J. Hepatol. 53, 1035\u20131040 (2010).","journal-title":"J. Hepatol."},{"key":"BFnrrheum2010214_CR91","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/hep.23239","volume":"50","author":"MF Abdelmalek","year":"2009","unstructured":"Abdelmalek, M. F.  et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50, 1818\u20131826 (2009).","journal-title":"Hepatology"},{"key":"BFnrrheum2010214_CR92","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ng.632","volume":"42","author":"JB Singer","year":"2010","unstructured":"Singer, J. B.  et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711\u2013714 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrrheum2010214_CR93","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/ng0810-650","volume":"42","author":"GP Aithal","year":"2010","unstructured":"Aithal, G. P. & Daly, A. K. Preempting and preventing drug-induced liver injury. Nat. Genet. 42, 650\u2013651 (2010).","journal-title":"Nat. Genet."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2010.214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2010.214","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2010.214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:26:25Z","timestamp":1684470385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2010.214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,25]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BFnrrheum2010214"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2010.214","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,25]]}}}